scholarly article | Q13442814 |
P50 | author | William G Wierda | Q64026278 |
Michael J. Keating | Q66429598 | ||
Jennifer A Woyach | Q90156409 | ||
Kumudha Balakrishnan | Q114427990 | ||
Fabiola Cervantes-Gomez | Q117256519 | ||
Betty Lamothe | Q117256520 | ||
P2093 | author name string | Varsha Gandhi | |
P2860 | cites work | The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy | Q24633214 |
Bcl-2 antagonists: a proof of concept for CLL therapy | Q26823996 | ||
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets | Q27683708 | ||
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
Chronic lymphocytic leukemia | Q28236621 | ||
An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia | Q29620690 | ||
High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells | Q30433183 | ||
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease | Q33398808 | ||
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial | Q33412064 | ||
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial | Q33419580 | ||
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies | Q33419789 | ||
Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL | Q33714712 | ||
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies | Q33893704 | ||
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase | Q34001339 | ||
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study | Q34240404 | ||
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 | ||
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab) | Q34508322 | ||
The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia | Q34542102 | ||
Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia | Q35022490 | ||
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
How I treat refractory CLL. | Q36276536 | ||
Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling | Q36782109 | ||
Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block | Q37480786 | ||
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia | Q37634897 | ||
From pathogenesis to treatment of chronic lymphocytic leukaemia | Q37643423 | ||
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy | Q37655012 | ||
Inhibiting B-cell receptor signaling pathways in chronic lymphocytic leukemia | Q37959298 | ||
Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape | Q38041898 | ||
"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia''. | Q38140625 | ||
Lymph node-induced immune tolerance in chronic lymphocytic leukaemia: a role for caveolin-1. | Q38325527 | ||
First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia | Q38380183 | ||
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. | Q38959765 | ||
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity | Q39056302 | ||
The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells | Q40069478 | ||
Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. | Q40455255 | ||
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation | Q42184742 | ||
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models | Q42708522 | ||
Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia | Q43096794 | ||
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia | Q46378902 | ||
Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. | Q53061290 | ||
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. | Q55070853 | ||
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells | Q86516013 | ||
P433 | issue | 16 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | leukemia | Q29496 |
ibrutinib | Q5984881 | ||
lymphocyte | Q715347 | ||
chronic lymphocytic leukemia | Q1088156 | ||
venetoclax | Q23671272 | ||
P304 | page(s) | 3705-3715 | |
P577 | publication date | 2015-03-31 | |
P1433 | published in | Clinical Cancer Research | Q332253 |
P1476 | title | Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia | |
P478 | volume | 21 |
Q64120024 | A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy |
Q89863923 | A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-P53 inhibitor in Diffuse Large B-Cell Lymphoma |
Q91735722 | A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia |
Q93023511 | An in vitro assay for biomarker discovery and dose prediction applied to ibrutinib plus venetoclax treatment of CLL |
Q64115279 | Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia |
Q28656335 | Applications of chemogenomic library screening in drug discovery |
Q41615108 | BCL2/Ki-67 index predict survival in germinal center B-cell-like diffuse large B-cell lymphoma |
Q39006397 | Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia |
Q50072188 | Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). |
Q30383411 | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. |
Q41848521 | Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia |
Q38739050 | Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT). |
Q56270980 | Chronic lymphocytic leukaemia |
Q39263974 | Chronic lymphocytic leukaemia genomics and the precision medicine era. |
Q37113544 | Chronic lymphocytic leukemia therapy: new targeted therapies on the way |
Q36746585 | Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells |
Q46055970 | Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells |
Q91283878 | Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia |
Q55447785 | Critical molecular pathways in CLL therapy. |
Q39325783 | Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies |
Q47136959 | Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes |
Q37702281 | Development of venetoclax for therapy of lymphoid malignancies. |
Q37370784 | Dimethyl celecoxib sensitizes gastric cancer cells to ABT-737 via AIF nuclear translocation |
Q39065374 | Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). |
Q36788133 | Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. |
Q89004911 | Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials |
Q47424531 | Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia |
Q46370948 | Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax |
Q58580676 | Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment? |
Q37209768 | High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells |
Q47340234 | How should we sequence and combine novel therapies in CLL? |
Q37688589 | Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. |
Q37725415 | Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells |
Q38943877 | Magic pills: new oral drugs to treat chronic lymphocytic leukemia. |
Q56514276 | Microenvironmental agonists generate phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL |
Q51160342 | Pathways and mechanisms of venetoclax resistance. |
Q47445525 | Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy |
Q53963822 | Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. |
Q38818283 | Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. |
Q57169180 | Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia |
Q41865162 | Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia |
Q39145934 | Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia |
Q38637652 | Rational combination strategies to enhance venetoclax activity and overcome resistance in hematologic malignancies |
Q38862525 | Recent advances in therapy of chronic lymphocytic leukaemia |
Q46318389 | Recent therapeutic advances in chronic lymphocytic leukemia |
Q90029186 | Relapsed CLL: sequencing, combinations, and novel agents |
Q89562799 | Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm |
Q47882529 | Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation |
Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
Q89866309 | Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia |
Q94671635 | Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies |
Q39456786 | Targeting BCL-2-like Proteins to Kill Cancer Cells |
Q38996888 | Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies |
Q38722012 | Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia. |
Q90047057 | Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer |
Q38744922 | Targeting of B-cell receptor signalling in B-cell malignancies. |
Q47166330 | The BCL-2 arbiters of apoptosis and their growing role as cancer targets |
Q37035832 | The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. |
Q38766548 | The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia |
Q43090573 | The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia |
Q28075683 | The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemia |
Q51014811 | The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. |
Q28075504 | The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia |
Q44633375 | The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax. |
Q38798849 | To Prime, or Not to Prime: That Is the Question |
Q41652556 | Tris (dibenzylideneacetone) dipalladium: a small-molecule palladium complex is effective in inducing apoptosis in chronic lymphocytic leukemia B-cells |
Q90593423 | Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study |
Q55069042 | Updates from the 2017 American Society of Hematology annual meeting: practice-changing studies in untreated chronic lymphocytic leukemia. |
Q47300370 | Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial |
Q90071201 | Venetoclax for the Treatment of Chronic Lymphocytic Leukemia |
Q90986744 | Venetoclax in chronic lymphocytic leukaemia: a possible cure? |
Q89834270 | Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells |
Q38853500 | Venetoclax: First Global Approval |
Q41070355 | Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. |